Showing 1,001 - 1,020 results of 1,284 for search '(( significant decrease decrease ) OR ( significant ((level decrease) OR (mean decrease)) ))~', query time: 0.54s Refine Results
  1. 1001
  2. 1002

    Related to Fig 1. by Mohammad Nafees Ansari (22232505)

    Published 2025
    “…<p>(<b>A, B</b>) Absolute quantitation (pmol/mg protein) (mean ± SEM, <i>n</i> = 27) of different species of ceramides (A) and glucosylceramides (B) shows higher levels in luminal tumor tissues (labeled as T) in comparison to adjacent normal tissues (labeled as N). …”
  3. 1003

    Table 1_The effects of magnesium and vitamin D/E co-supplementation on inflammation markers and lipid metabolism of obese/overweight population: a systematic review and meta-analys... by Kai Deng (299054)

    Published 2025
    “…In contrast, the serum levels of interleukin-6 (IL-6) showed a non-significant decrease (MD: −0.09, 95%CI: −0.33, 0.15, p = 0.46), and did not significantly affect lipid metabolism according to levels of parameters such as serum triglyceride (MD = 1.84, 95% CI: −28.92, 32.60, p = 0.91), serum LDL-c (MD: −4.56, 95% CI: −14.19, 5.08, p = 0.35), and serum HDL-c (MD: 1.96, 95% CI: −3.07, 6.98, p = 0.45) in the co-supplementation of magnesium and Vitamin E.…”
  4. 1004

    Table 1_Health care resource use and costs associated with adult pneumococcal disease in the United States from 2017 to 2019, stratified by age and health risk: a retrospective coh... by Nicole Cossrow (473898)

    Published 2025
    “…</p>Conclusion<p>Targeting PD prevention efforts to high-risk groups based on age and/or health risk level could decrease the clinical and economic burden of adult PD in the US.…”
  5. 1005

    Table 2_The impact of long-term trends in continuity of care on the medical expenses of hypertensive patients: based on group-based trajectory model.xlsx by Yanqiu Du (6817550)

    Published 2025
    “…Patients in the high-level maintenance group incurred the lowest annual medical expenses (mean range: ¥3,786–¥5,088), while the low-level maintenance group exhibited the highest (mean range: ¥6,450–¥10,321). …”
  6. 1006

    Table 1_The impact of long-term trends in continuity of care on the medical expenses of hypertensive patients: based on group-based trajectory model.docx by Yanqiu Du (6817550)

    Published 2025
    “…Patients in the high-level maintenance group incurred the lowest annual medical expenses (mean range: ¥3,786–¥5,088), while the low-level maintenance group exhibited the highest (mean range: ¥6,450–¥10,321). …”
  7. 1007

    Table 3_The impact of long-term trends in continuity of care on the medical expenses of hypertensive patients: based on group-based trajectory model.xlsx by Yanqiu Du (6817550)

    Published 2025
    “…Patients in the high-level maintenance group incurred the lowest annual medical expenses (mean range: ¥3,786–¥5,088), while the low-level maintenance group exhibited the highest (mean range: ¥6,450–¥10,321). …”
  8. 1008

    Effect of treatments on pH, conductivity, and biological oxygen demand (BOD) over time. by Khomsan Ruangrit (20833447)

    Published 2025
    “…Error bars represent standard deviations from the mean. Letters above the data points represent significant differences between treatments on the same day (Tukey’s HSD test, p <  0.05). …”
  9. 1009

    Data Sheet 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  10. 1010

    Data Sheet 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  11. 1011

    Table 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  12. 1012

    Table 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  13. 1013

    Supplementary Material for: Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Months Naturalistic Study by Brenna I.H. (19773549)

    Published 2024
    “…The majority of the MITT population (84; 60.9%) completed 24 weeks of treatment in the study. There was a significant decrease in the overall use of opioids (p<0.001) and the use of alcohol and other illicit substances was low. …”
  14. 1014

    Image1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.tif by Xiaozhen Huang (5858690)

    Published 2024
    “…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”
  15. 1015

    Table1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.docx by Xiaozhen Huang (5858690)

    Published 2024
    “…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”
  16. 1016

    The Impact of Mindfulness-Based Intervention on Reducing Aggressive Behaviour and Promoting Student Wellbeing in Sports by Moruf Adebayo Abidogun (13491958)

    Published 2025
    “…The results indicate a significant reduction in aggressive behaviour among the experimental group compared to the control group, with a marked decrease in verbal and physical aggression. …”
  17. 1017

    Table 2_Effect of dietary glycemic index on insulin resistance in adults without diabetes mellitus: a systematic review and meta-analysis.docx by Yu-Ting Yu (20717441)

    Published 2025
    “…<p>Low glycemic index (LoGI) diets are associated with decreased insulin resistance and are an effective strategy for patients with diabetes mellitus to control postprandial glucose levels. …”
  18. 1018

    Table 1_Effect of dietary glycemic index on insulin resistance in adults without diabetes mellitus: a systematic review and meta-analysis.docx by Yu-Ting Yu (20717441)

    Published 2025
    “…<p>Low glycemic index (LoGI) diets are associated with decreased insulin resistance and are an effective strategy for patients with diabetes mellitus to control postprandial glucose levels. …”
  19. 1019

    Table 1_Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study.docx by Lin Tao (4236)

    Published 2025
    “…Clinical data before treatment (baseline) and after 4, 12, and 24 weeks of treatment were analyzed and safety assessed.</p>Results<p>Mean serum creatinine and eGFR levels remained stable in all three groups. …”
  20. 1020